A single dose of cilta-cel yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Patients with fewer prior lines of therapy in which they were exposed or refractory to alkylators generally had better outcomes.
Researchers sought to determine whether therapy with carfilzomib, lenalidomide, and dexamethasone would be effective for patients with newly diagnosed multiple myeloma.
Researchers sought to determine if there would be a survival benefit with daratumumab combined with lenalidomide and dexamethasone in patients with transplant-ineligible MM.
Adding isatuximab to carfilzomib and dexamethasone also improved the depth of response.
Researchers sought to determine whether there was an association between NPDs and CAR-T therapy in patients with multiple myeloma.
After initial triple-class exposure, most patients received a combination of triple-class agents and other agents.
The median age of trial participants was 3.8 years younger than the median age of the real-world population.
Patients with active multiple myeloma may have insufficient responses to mRNA COVID-19 vaccines.
Researchers sought to determine whether ixazomib and dexamethasone would be more effective vs physician’s choice of treatment in relapsed or refractory AL amyloidosis.
